Search results for: 'Sample-to-Answer'

16 Aug 2016  |  North America  |  Market Research

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Emerging Business Models Drive Transformation

Infographics

×

The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to comme...

The global pharmaceutical market is projected to reach approximately $1.72 trillion in 2026, with large molecules driving most incremental growth while small molecules remain the sector’s cash flow base. The current growth cycle concentrates on cardiometabolic and oncology, led by GLP-1 platforms and antibody–drug conjugates (ADCs). Competitive adv...

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promis...

The study presents an in-depth exploration of novel functional ingredients designed to enhance mental and emotional well-being, identifying the overall drivers of growth, technological change, and market opportunities through 2030. Mental health disorders continue to present a serious global challenge, with anxiety and depression affecting more tha...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

As the industry continues to innovate across novel small- and large-molecule therapies, including RNA-targeted small molecules, cell and gene therapies, and mRNA therapies, pharma sponsors increasingly rely on partners for technology access, database generation and analysis, and preclinical and clinical research.These disruptions continue to drive ...

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clini...

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...